EDAP TMS Confirms Success of HIFU With Ablatherm at the 20th Congress of the European Association of Urology, Istanbul
24 Marzo 2005 - 10:30AM
PR Newswire (US)
EDAP TMS Confirms Success of HIFU With Ablatherm at the 20th
Congress of the European Association of Urology, Istanbul Studies
at 8 Years Show Lower Side Effects, Preserved Quality of Life LYON,
France, March 24 /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(NASDAQ:EDAP), today confirms the success of HIFU with Ablatherm at
the 20th Congress of the European Association of Urology (E.A.U.),
held March 16-19, 2005 in Istanbul. The Congress represents the
pan-European urological community accounting for more than 16,000
members and is considered one of the year's keynote events with
more than 7,000 attendees. Ablatherm users presented the latest
clinical results obtained using EDAP's HIFU technology for the
treatment of prostate cancer. Dr. Stefan Thuroff, from Harlaching
Hospital, Munich, Germany, presented an eight-year follow-up study
of more than 1,000 patients treated with Ablatherm. The results
showed no severe systemic side effects thus preserving the quality
of life for the patients treated with Ablatherm. The study
confirmed sustained clinical results at eight years and
demonstrated that HIFU treatment does not exclude other therapeutic
options afterwards. Dr. Albert Gelet, from Edouard Herriot
Hospital, Lyon, France, further validated the success rates of HIFU
applied to patients who failed radiotherapy treatment. Based on a
study of more than 100 patients treated, with an average follow-up
of 15.7 months, Dr. Gelet's results showed an 84% success rate
(negative biopsy and PSA below 0.5) with no rectal damage under
dedicated parameters. The HIFU-related side effects were
statistically lower than the side effects reported after other
types of salvage therapy. Hugues de Bantel, Chief Executive Officer
of EDAP TMS, commented: "With these positive and long-term results
presented during scientific sessions, the EDAP booth was well
attended. Urologists showed a true interest in Ablatherm and its
technology. While discussing the technology with opinion leaders
who have been using the Ablatherm for years, urologists clearly
showed they were convinced of the success and benefits of this
therapy based on the number of patients treated to date with
Ablatherm, the number of peer reviewed articles published
specifically on HIFU with Ablatherm and the now more than 63
clinical sites using Ablatherm. Based on the activity and response
at the Congress, we remain confident in our continued growth rates
through increased patient demand at existing clinical sites as well
as additional installations of Ablatherm units in a number of
prospective sites. During the E.A.U. Congress, a group of leading
European urologists from key markets including Germany, Belgium,
the UK, Italy, and France launched the European HIFU Club to help
grow understanding and support of HIFU technology by monitoring its
developments and progress and by educating the urology community
about its benefits, its clinical applications, patient selection
and follow-up. The Club will serve as a forum for current HIFU
users to exchange views and discuss ways of optimizing treatment
outcomes. Pr. Pierre Teillac, General Secretary of the E.A.U.,
commented: "We have seen the use of HIFU technology for the
treatment of localized prostate cancer spreading rapidly across
Europe over the last few years. The creation of a HIFU Club where
clinical experience and knowledge can be shared within the urology
community and beyond was well overdue, and I strongly welcome this
initiative." Dr. Thuroff of Germany, added: "HIFU technology for
the treatment of prostate cancer is very promising, as is
demonstrated by the high rate of success that we experienced in
Munich. HIFU will not outdate other, more established, therapies
overnight, and it is today mainly targeted at specific groups of
patients. However, it dramatically broadens the range of treatment
options." Hugues de Bantel Chief Executive Officer of EDAP TMS,
concluded: "The launch of a European HIFU Club, initiated and
supported by the European Association of Urology, further validates
the recognition of HIFU technology as a therapeutic option for
localized prostate cancer by the medical community. We are very
enthusiastic about this initiative as it will help spread the
understanding of HIFU technology to a wider audience." About EDAP
TMS S.A. EDAP TMS S.A. develops and markets Ablatherm, the most
advanced and clinically proven choice for High Intensity Focused
Ultrasound (HIFU) treatment of localized prostate cancer. HIFU
treatment is shown to be a minimally invasive and effective
treatment option with a low occurrence of side effects. The company
is also developing this technology for the treatment of certain
other types of tumors. EDAP TMS S.A. also produces and
commercializes medical equipment for treatment of urinary tract
stones using Extra-corporeal Shockwave Lithotripsy (ESWL). For more
information on the Company, contact the Investor Relations Dept by
phone at +33 (0)4 78 26 40 46 or see the Company's Web site at:
http://www.edap-tms.com/ . This press release contains, in addition
to historical information, forward-looking statements that involve
risks and uncertainties. These include statements regarding the
Company's growth and expansion plans. Such statements are based on
management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ
materially from those described in the forward-looking statements.
Factors that may cause such a difference include, but are not
limited to, those described in the Company's filings with the
Securities and Exchange Commission. CONTACT: EDAP TMS S.A. Hugues
de Bantel - Philippe Chauveau Blandine Confort +33 4 78 26 40 46
Halliburton Investor Relations Matt Kreps - Geralyn DeBusk 972 458
8000 DATASOURCE: EDAP TMS S.A. CONTACT: Hugues de Bantel, Philippe
Chauveau, or Blandine Confort, all of EDAP TMS S.A.,
+33-4-78-26-40-46; or Matt Kreps or Geralyn DeBusk, both of
Halliburton Investor Relations, +1-972-458-8000, for EDAP TMS S.A.
Web site: http://www.edap-tms.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024